Open trial of Bruton’s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus
Elizabeth C. Goodale(University of California, Davis), Catherine A. Outerbridge(Veterinary Medical Teaching Hospital), Tyler J. M. Jordan(Veterinary Medical Teaching Hospital), Mohammad R. Masjedizadeh(Principia Biopharma (United States)), Stephen D. White(Veterinary Medical Teaching Hospital), Michelle Francesco(Gene Therapy Laboratory), Ronald J. Hill(The University of Sydney), Angelina Bisconte(Principia Biopharma (United States)), Steven G. Gourlay(Principia Biopharma (United States)), Petra Bizikova(North Carolina State University), Carolyn B. Emery(Veterinary Medical Teaching Hospital), Dédée F. Murrell(Sutherland Hospital), Philip A. Nunn(Principia Biopharma (United States)), Dori L. Borjesson(Washington State University)
Cited by 26
Related Papers
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
|Nature Immunology|2008|1.5k
Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification
|Journal of the American Academy of Dermatology|2014|933
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB
|Journal of the American Academy of Dermatology|2008|933
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
|British Journal of Dermatology|2020|778
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586